We use cookies to improve your experience. By continuing to browse this site, you accept our cookie policy.×
Skip main navigation
Aging Health
Bioelectronics in Medicine
Biomarkers in Medicine
Breast Cancer Management
CNS Oncology
Colorectal Cancer
Concussion
Epigenomics
Future Cardiology
Future Medicine AI
Future Microbiology
Future Neurology
Future Oncology
Future Rare Diseases
Future Virology
Hepatic Oncology
HIV Therapy
Immunotherapy
International Journal of Endocrine Oncology
International Journal of Hematologic Oncology
Journal of 3D Printing in Medicine
Lung Cancer Management
Melanoma Management
Nanomedicine
Neurodegenerative Disease Management
Pain Management
Pediatric Health
Personalized Medicine
Pharmacogenomics
Regenerative Medicine
Research Article

Berberine–phospholipid nanoaggregate-embedded thiolated chitosan hydrogel for aphthous stomatitis treatment

    Yasaman Hashtrodylar

    Department of Pharmaceutics & Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, 1996835113, Tehran, Iran

    ,
    Shahram Rabbani

    Research Center for Advanced Technologies in Cardiovascular Medicine, Cardiovascular Diseases Research Institute, Tehran University of Medical Sciences, 1313814117, Tehran, Iran

    ,
    Simin Dadashzadeh

    Department of Pharmaceutics & Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, 1996835113, Tehran, Iran

    &
    Azadeh Haeri

    *Author for correspondence: Tel.: +98 218 820 0073;

    E-mail Address: a_haeri@sbmu.ac.ir

    Department of Pharmaceutics & Pharmaceutical Nanotechnology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, 1996835113, Tehran, Iran

    Protein Technology Research Center, Shahid Beheshti University of Medical Sciences, 1996835113, Tehran, Iran

    Published Online:https://doi.org/10.2217/nnm-2023-0009

    Aim: This study aimed to develop nanoaggregates of berberine–phospholipid complex incorporated into thiolated chitosan (TCS) hydrogel for the treatment of aphthous stomatitis. Methods: The berberine–phospholipid complex was formulated through the solvent evaporation technique and assembled into nanoaggregates. TCS was synthesized through the attachment of thioglycolic acid to chitosan (CS). Nanoaggregates–TCS was prepared by the incorporation of nanoaggregates into TCS and underwent in vitro and in vivo tests. Results: Nanoaggregates–TCS exhibited prolonged release of berberine. The mucoadhesive strength of nanoaggregates–TCS increased 1.75-fold compared with CS hydrogel. In vivo studies revealed the superior therapeutic efficacy of nanoaggregates–TCS compared with that of other groups. Conclusion: Due to prolonged drug release, appropriate residence time and anti-inflammatory effects, nanoaggregates–TCS is an effective system for the treatment of aphthous stomatitis.

    Graphical abstract

    Papers of special note have been highlighted as: • of interest; •• of considerable interest

    References

    • 1. Akintoye SO, Greenberg MS. Recurrent aphthous stomatitis. Dent. Clin. North Am. 58(2), 281–297 (2014).
    • 2. Hosseinpour-Moghadam R, Mehryab F, Torshabi M, Haeri A. Applications of novel and nanostructured drug delivery systems for the treatment of oral cavity diseases. Clin. Ther. 43(12), e377–e402 (2021). •• Provides an extensive review of drug-delivery systems for oral cavity diseases.
    • 3. Dalessandri D, Zotti F, Laffranchi L et al. Treatment of recurrent aphthous stomatitis (RAS; aphthae; canker sores) with a barrier forming mouth rinse or topical gel formulation containing hyaluronic acid: a retrospective clinical study. BMC Oral Health 19(1), 153 (2019).
    • 4. Chiang CP, Yu-Fong Chang J, Wang YP et al. Recurrent aphthous stomatitis – etiology, serum autoantibodies, anemia, hematinic deficiencies, and management. J. Formos. Med. Assoc. 118(9), 1279–1289 (2019). •• Provides an informative review of recurrent aphthous stomatitis.
    • 5. Belenguer-Guallar I, Jiménez-Soriano Y, Claramunt-Lozano A. Treatment of recurrent aphthous stomatitis. A literature review. J. Clin. Exp. Dent. 6(2), e168–e174 (2014).
    • 6. Khademi H, Iranmanesh P, Moeini A, Tavangar A. Evaluation of the effectiveness of the iralvex gel on the recurrent aphthous stomatitis management. Int. Sch. Res. Notices 175378 (2014).
    • 7. Rasic A, Kapo B, Avdicevic A et al. Efficacy and safety of lysozyme, cetylpyridinium and lidocaine fixed combination for treatment of chemotherapy- and radiotherapy-induced oral mucositis: a pilot study. Mater. Sociomed. 31(3), 166–171 (2019).
    • 8. Yang Y, Zhang T, Dong Z et al. Short-term efficacy of Pudilan Keyanning toothpaste in treatment of minor recurrent aphthous ulcers. Evid. Based Complement Alternat. Med. 9125327 (2016).
    • 9. Liu C, Zhou Z, Liu G et al. Efficacy and safety of dexamethasone ointment on recurrent aphthous ulceration. Am. J. Med. 125(3), 292–301 (2012).
    • 10. Karavana SY, Gökçe EH, Rençber S et al. A new approach to the treatment of recurrent aphthous stomatitis with bioadhesive gels containing cyclosporine A solid lipid nanoparticles: in vivo/in vitro examinations. Int. J. Nanomed. 7, 5693–5704 (2012).
    • 11. El-Wakeel NM, Dawoud MHS. Topical insulin-liposomal formulation in management of recurrent aphthous ulcers: a randomized placebo-controlled trial. J. Investig. Clin. Dent. 10(4), e12437 (2019).
    • 12. Arafa MG, Ghalwash D, El-Kersh DM, Elmazar MM. Propolis-based niosomes as oromuco-adhesive films: a randomized clinical trial of a therapeutic drug delivery platform for the treatment of oral recurrent aphthous ulcers. Sci. Rep. 8(1), 1–14 (2018).
    • 13. Carvalho JPF, Silva ACQ, Bastos V et al. Nanocellulose-based patches loaded with hyaluronic acid and diclofenac towards aphthous stomatitis treatment. Nanomaterials (Basel) 10(4), 628 (2020).
    • 14. Soleymani S, Farzaei MH, Zargaran A, Niknam S, Rahimi R. Promising plant-derived secondary metabolites for treatment of acne vulgaris: a mechanistic review. Arch. Dermatol. Res. 312(1), 5–23 (2020).
    • 15. Wang K, Feng X, Chai L, Cao S, Qiu F. The metabolism of berberine and its contribution to the pharmacological effects. Drug Metab. Rev. 49(2), 139–157 (2017). • Provides an informative review of berberine pharmacokinetics and its pharmacological effects.
    • 16. Ehteshamfar SM, Akhbari M, Afshari JT et al. Anti-inflammatory and immune-modulatory impacts of berberine on activation of autoreactive T cells in autoimmune inflammation. J. Cell. Mol. Med. 24(23), 13573–13588 (2020).
    • 17. Sahibzada MUK, Sadiq A, Faidah HS et al. Berberine nanoparticles with enhanced in vitro bioavailability: characterization and antimicrobial activity. Drug Des. Devel. Ther. 12, 303–312 (2018).
    • 18. Jiang XW, Zhang Y, Zhu YL et al. Effects of berberine gelatin on recurrent aphthous stomatitis: a randomized, placebo-controlled, double-blind trial in a Chinese cohort. Oral. Surg. Oral. Med. Oral. Pathol. Oral. Radiol. Endod. 115(2), 212–217 (2013).
    • 19. Elsheikh MA, Elnaggar YSR, Otify DY, Abdallah OY. Bioactive-chylomicrons for oral lymphatic targeting of berberine chloride: novel flow-blockage assay in tissue-based and Caco-2 cell line models. Pharm. Res. 35(1), 18 (2018).
    • 20. Cui HX, Hu YN, Li JW, Yuan K, Guo Y. Preparation and evaluation of antidiabetic agents of berberine organic acid salts for enhancing the bioavailability. Molecules 24(1), 103 (2018).
    • 21. Khan J, Alexander A, Ajazuddin, Saraf S, Saraf S. Recent advances and future prospects of phyto-phospholipid complexation technique for improving pharmacokinetic profile of plant actives. J. Control. Rel. 168(1), 50–60 (2013).
    • 22. Laffleur F. Mucoadhesive polymers for buccal drug delivery. Drug Dev. Ind. Pharm. 40(5), 591–598 (2014).
    • 23. Marques AC, Rocha AI, Leal P, Estanqueiro M, Lobo JMS. Development and characterization of mucoadhesive buccal gels containing lipid nanoparticles of ibuprofen. Int. J. Pharm. 533(2), 455–462 (2017).
    • 24. Abourehab MAS, Pramanik S, Abdelgawad MA et al. Recent advances of chitosan formulations in biomedical applications. Int. J. Mol. Sci. 23(18), 10975 (2022).
    • 25. Kumar A, Vimal A, Kumar A. Why chitosan? From properties to perspective of mucosal drug delivery. Int. J. Biol. Macromol. 91, 615–622 (2016).
    • 26. Hemmingsen LM, Škalko-Basnet N, Jøraholmen MW. The expanded role of chitosan in localized antimicrobial therapy. Mar. Drugs 19(12), 697 (2021).
    • 27. Alven S, Aderibigbe BA. Chitosan and cellulose-based hydrogels for wound management. Int. J. Mol. Sci. 21(24), 9656 (2020).
    • 28. Duggan S, Cummins W, O'Donovan O, Hughes H, Owens E. Thiolated polymers as mucoadhesive drug delivery systems. Eur. J. Pharm. Sci. 100, 64–78 (2017). •• Provides an informative review of thiomers.
    • 29. Federer C, Kurpiers M, Bernkop-Schnürch A. Thiolated chitosans: a multi-talented class of polymers for various applications. Biomacromolecules 22(1), 24–56 (2021).
    • 30. Kast CE, Bernkop-Schnürch A. Thiolated polymers – thiomers: development and in vitro evaluation of chitosan–thioglycolic acid conjugates. Biomaterials 22(17), 2345–2352 (2001).
    • 31. Gajendiran M, Rhee JS, Kim K. Recent developments in thiolated polymeric hydrogels for tissue engineering applications. Tissue Eng. Part B Rev. 24(1), 66–74 (2018).
    • 32. Vaezi H, Rabbani S, Mortazavi SA, Kamalinejad M, Haeri A. Fabrication, in vitro, and in vivo characterization of mucoadhesive berberine-loaded blended wafers for treatment of chemotherapy-induced oral mucositis. AAPS PharmSciTech 24(1), 19 (2023).
    • 33. Mardani M, Sadeghzadeh A, Tanideh N et al. The effects of adipose tissue-derived stem cells seeded onto the curcumin-loaded collagen scaffold in healing of experimentally-induced oral mucosal ulcers in rat. Iran. J. Basic Med. Sci. 23(12), 1618–1627 (2020).
    • 34. Deyhimi P, Khademi H, Birang R, Akhoondzadeh M. Histological evaluation of wound healing process after photodynamic therapy of rat oral mucosal ulcer. J. Dent. (Shiraz) 17(1), 43–48 (2016).
    • 35. Kohli K, Mujtaba A, Malik R et al. Development of natural polysaccharide-based nanoparticles of berberine to enhance oral bioavailability: formulation, optimization, ex vivo, and in vivo assessment. Polymers (Basel) 13(21), 3833 (2021).
    • 36. Freag MS, Saleh WM, Abdallah OY. Self-assembled phospholipid-based phytosomal nanocarriers as promising platforms for improving oral bioavailability of the anticancer celastrol. Int. J. Pharm. 535(1–2), 18–26 (2018).
    • 37. Akhlaghi S, Rabbani S, Karimi H, Haeri A. Hyaluronic acid gel incorporating curcumin–phospholipid complex nanoparticles prevents postoperative peritoneal adhesion. J. Pharm. Sci. 112(2), 587–598 (2023).
    • 38. Yu F, Li Y, Chen Q et al. Monodisperse microparticles loaded with the self-assembled berberine–phospholipid complex-based phytosomes for improving oral bioavailability and enhancing hypoglycemic efficiency. Eur. J. Pharm. Biopharm. 103, 136–148 (2016).
    • 39. Aldawsari MF, Khafagy ES, Alotaibi HF, Abu Lila AS. Vardenafil-loaded bilosomal mucoadhesive sponge for buccal delivery: optimization, characterization, and in vivo evaluation. Polymers (Basel) 14(19), 4184 (2022).
    • 40. Müller C, Ma BN, Gust R, Bernkop-Schnürch A. Thiopyrazole preactivated chitosan: combining mucoadhesion and drug delivery. Acta Biomater. 9(5), 6585–6593 (2013).
    • 41. Fan B, Xing Y, Zheng Y, Sun C, Liang G. pH-Responsive thiolated chitosan nanoparticles for oral low-molecular weight heparin delivery: in vitro and in vivo evaluation. Drug Deliv. 23(1), 238–247 (2016).
    • 42. Liu X, Yu B, Huang Q et al. In vitro BMP-2 peptide release from thiolated chitosan based hydrogel. Int. J. Biol. Macromol. 93(Pt A), 314–321 (2016).
    • 43. Babadi D, Dadashzadeh S, Osouli M, Daryabari MS, Haeri A. Nanoformulation strategies for improving intestinal permeability of drugs: a more precise look at permeability assessment methods and pharmacokinetic properties changes. J. Control. Rel. 321, 669–709 (2020). •• Provides an informative review of oral nanoformulations.
    • 44. Hua S. Advances in nanoparticulate drug delivery approaches for sublingual and buccal administration. Front. Pharmacol. 10, 1328 (2019).
    • 45. Kuche K, Bhargavi N, Dora CP, Jain S. Drug–phospholipid complex – a go through strategy for enhanced oral bioavailability. AAPS PharmSciTech 20(2), 43 (2019).
    • 46. Li H, Lu S, Luo M et al. A matrix dispersion based on phospholipid complex system: preparation, lymphatic transport, and pharmacokinetics. Drug Dev. Ind. Pharm. 46(4), 557–565 (2020).
    • 47. Chi C, Zhang C, Liu Y et al. Phytosome-nanosuspensions for silybin–phospholipid complex with increased bioavailability and hepatoprotection efficacy. Eur. J. Pharm. Sci. 144, 105212 (2020).
    • 48. Biswas S, Mukherjee PK, Kar A et al. Optimized piperine–phospholipid complex with enhanced bioavailability and hepatoprotective activity. Pharm. Dev. Technol. 26(1), 69–80 (2021).
    • 49. Ebada HMK, Nasra MMA, Elnaggar YSR, Abdallah OY. Novel rhein–phospholipid complex targeting skin diseases: development, in vitro, ex vivo, and in vivo studies. Drug Deliv. Transl. Res. 11(3), 1107–1118 (2021).
    • 50. Wang W, Zhang W, Jiang Y et al. Preparation of ursolic acid–phospholipid complex by solvent-assisted grinding method to improve dissolution and oral bioavailability. Pharm. Dev. Technol. 25(1), 68–75 (2020).
    • 51. Dora CP, Kushwah V, Katiyar SS et al. Improved oral bioavailability and therapeutic efficacy of erlotinib through molecular complexation with phospholipid. Int. J. Pharm. 534(1–2), 1–13 (2017).
    • 52. Nowroozi F, Almasi A, Javidi J, Haeri A, Dadashzadeh S. Effect of surfactant type, cholesterol content and various downsizing methods on the particle size of niosomes. Iran. J. Pharm. Res. 17(Suppl. 2), S1–S11 (2018).
    • 53. Xie J, Li Y, Song L et al. Design of a novel curcumin–soybean phosphatidylcholine complex-based targeted drug delivery systems. Drug Deliv. 24(1), 707–719 (2017).
    • 54. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: the gastrointestinal mucus barriers. Adv. Drug Deliv. Rev. 64(6), 557–570 (2012).
    • 55. Griesser J, Hetényi G, Bernkop-Schnürch A. Thiolated hyaluronic acid as versatile mucoadhesive polymer: from the chemistry behind to product developments – what are the capabilities? Polymers (Basel) 10(3), 243 (2018).
    • 56. Dubashynskaya NV, Petrova VA, Romanov DP, Skorik YA. pH-sensitive drug delivery system based on chitin nanowhiskers–sodium alginate polyelectrolyte complex. Materials (Basel) 15(17), 5860 (2022).
    • 57. Bhavsar C, Momin M, Gharat S, Omri A. Functionalized and graft copolymers of chitosan and its pharmaceutical applications. Expert Opin. Drug Deliv. 14(10), 1189–1204 (2017).
    • 58. Zhao W, Kong M, Feng C et al. Investigation of gelling behavior of thiolated chitosan in alkaline condition and its application in stent coating. Carbohydr. Polym. 136, 307–315 (2016).
    • 59. Mahmood A, Lanthaler M, Laffleur F, Huck CW, Bernkop-Schnürch A. Thiolated chitosan micelles: highly mucoadhesive drug carriers. Carbohydr. Polym. 167, 250–258 (2017).
    • 60. Phadungcharoen N, Patrojanasophon P, Opanasopit P et al. Smartphone-based Ellman's colourimetric methods for the analysis of d-penicillamine formulation and thiolated polymer. Int. J. Pharm. 558, 120–127 (2019).
    • 61. Gong J, Wang L, Wu J et al. The rheological and physicochemical properties of a novel thermosensitive hydrogel based on konjac glucomannan/gum tragacanth. LWT 100, 271–277 (2019).
    • 62. Zeng Z, Mo XM, He C et al. An in situ forming tissue adhesive based on poly(ethylene glycol)-dimethacrylate and thiolated chitosan through the Michael reaction. J. Mater. Chem. B 4(33), 5585–5592 (2016).
    • 63. Yang IH, Lin IE, Chen TC et al. Synthesis, characterization, and evaluation of BDDE crosslinked chitosan-TGA hydrogel encapsulated with genistein for vaginal atrophy. Carbohydr. Polym. 260, 117832 (2021).
    • 64. Liu Q, Xue J, Zhang X et al. The influence of a biomimetic pulmonary surfactant modification on the in vivo fate of nanoparticles in the lung. Acta Biomater. 147, 391–402 (2022).
    • 65. Dos Santos Ramos MA, da Silva PB, de Toledo LG et al. Intravaginal delivery of Syngonanthus nitens (Bong.) Ruhland fraction based on a nanoemulsion system applied to vulvovaginal candidiasis treatment. J. Biomed. Nanotechnol. 15(5), 1072–1089 (2019).
    • 66. Khodaverdi E, Tafaghodi M, Ganji F, Abnoos K, Naghizadeh H. In vitro insulin release from thermosensitive chitosan hydrogel. AAPS PharmSciTech 13(2), 460–466 (2012).
    • 67. Gu B, Sun X, Papadimitrakopoulos F, Burgess DJ. Seeing is believing, PLGA microsphere degradation revealed in PLGA microsphere/PVA hydrogel composites. J. Control. Rel. 228, 170–178 (2016).
    • 68. Stojkov G, Niyazov Z, Picchioni F, Bose RK. Relationship between structure and rheology of hydrogels for various applications. Gels 7(4), 255 (2021).
    • 69. Liu X, Chen Y, Huang Q et al. A novel thermo-sensitive hydrogel based on thiolated chitosan/hydroxyapatite/beta-glycerophosphate. Carbohydr. Polym. 110, 62–69 (2014).
    • 70. Peppas NA, Khare AR. Preparation, structure and diffusional behavior of hydrogels in controlled release. Adv. Drug Deliv. Rev. 11(1), 1–35 (1993).
    • 71. Abd El-Hady MM, Saeed SE. Antibacterial properties and pH sensitive swelling of in situ formed silver–curcumin nanocomposite based chitosan hydrogel. Polymers (Basel) 12(11), 2451 (2020).
    • 72. Chen C, Wang L, Deng L, Hu R, Dong A. Performance optimization of injectable chitosan hydrogel by combining physical and chemical triple crosslinking structure. J. Biomed. Mater. Res. A 101(3), 684–693 (2013).
    • 73. Sun QB, Xu CP, Li WQ, Meng QJ, Qu HZ. Halloysites modified polyethylene glycol diacrylate/thiolated chitosan double network hydrogel combined with BMP-2 for rat skull regeneration. Artif. Cells Nanomed. Biotechnol. 49(1), 71–82 (2021).
    • 74. Andersson M, Axelsson A, Zacchi G. Swelling kinetics of poly(N-isopropylacrylamide) gel. J. Control. Rel. 50(1–3), 273–281 (1998).
    • 75. Bahulkar SS, Munot NM, Surwase SS. Synthesis, characterization of thiolated karaya gum and evaluation of effect of pH on its mucoadhesive and sustained release properties. Carbohydr. Polym. 130, 183–190 (2015).
    • 76. Andrews GP, Laverty TP, Jones DS. Mucoadhesive polymeric platforms for controlled drug delivery. Eur. J. Pharm. Biopharm. 71(3), 505–518 (2009).
    • 77. Sandri G, Rossi S, Ferrari F, Bonferoni MC, Caramella CM. Mucoadhesive polymers as enabling excipients for oral mucosal drug delivery. Oral Mucosal Drug Deliv. Therapy 53–88 (2015).
    • 78. Bernkop-Schnürch A, Kast CE, Richter MF. Improvement in the mucoadhesive properties of alginate by the covalent attachment of cysteine. J. Control. Rel. 71(3), 277–285 (2001).
    • 79. Du L, Feng X, Xiang X, Jin Y. Wound healing effect of an in situ forming hydrogel loading curcumin–phospholipid complex. Curr. Drug Deliv. 13(1), 76–82 (2016).
    • 80. Moreno M, Pow PY, Tabitha TST et al. Modulating release of ranibizumab and aflibercept from thiolated chitosan-based hydrogels for potential treatment of ocular neovascularization. Expert Opin. Drug Deliv. 14(8), 913–925 (2017).